2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 嘉事堂药业股份有限公司 董事会议事规则 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 董事会与董事长的职权 1 | | 第三章 | 董事会会议制度 3 | | 第四章 | 董事会议事程序 4 | | 第五章 | 董事会会议的信息披露 7 | | 第六章 | 董事会决议案的执行和反馈 7 | | 第七章 | 附则 8 | 第一章 总则 第一条 为了确保嘉事堂药业股份有限公司（以下简称"公司"）董 事会落实股东会决议，确保董事会做出科学、迅速和谨慎的决策，规范董 事会的议事程序，根据《中华人民共和国公司法》等有关法律、行政法规、 部门规章和《嘉事堂药业股份有限公司章程》（以下简称"《公司章程》"）， 特制定本规则。 第二章 董事会与董事长的职权 第二条 根据《公司章程》的有关规定，董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的年度财务预算方案、决算方案； （五）制订公司的利润分配方案和弥补亏损方案； （六）制订 ...

嘉事堂药业股份有限公司公司章程 嘉事堂药业股份有限公司章程 2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 | | | | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 6 | | 第四章 | 党委 7 | | 第五章 | 股东和股东会 8 | | 第一节 | 股东的一般规定 8 | | 第二节 | 控股股东和实际控制人 11 | | 第三节 | 股东会的一般规定 13 | | 第四节 | 股东会的召集 15 | | 第五节 | 股东会的提案与通知 17 | | 第六节 | 股东会的召开 19 | | 第七节 | 股东会的表决和决议 22 | | 第六章 | 董事和董事会 28 | | 第一节 | 董事的一般规定 28 | | 第二节 | 董事会 32 | | 第三节 | 独立董事 38 | | 第四节 | 董事会专门委员会 42 | | 第七章 | 审计委员会 43 | | 第八章 | 总裁及其他高级管理人员 45 | | 第九 ...

2. 本法律意见书制作过程中，承办律师已按照中国现行法律、法规的要求， 对与出具本法律意见书有关的文件资料进行了必要审查。 北京市安理律师事务所 关于嘉事堂药业股份有限公司 2025 年第二次临时股东大会的法律意见书 文件编号：安理法意（2025）嘉字第 071601 号 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张善古律师、王瑞欣律师（以下 简称"承办律师"）担任嘉事堂药业股份有限公司于 2025 年 7 月 16 日召开的 2025 年第二次临时股东大会（以下简称"本次股东大会"）特别法律顾问，出席 会议，并出具本法律意见书。 本法律意见书系依据《中华人民共和国证券法》（以下简称"证券法"）、 《中华人民共和国公司法》（以下简称"公司法"）、中国证券监督管理委员会 《上市公司股东大会规则》（以下简称"股东大会规则"）、《深圳证券交易所 股票上市规则》等规范性文件及《嘉事堂药业股份有限公司章程》（以下简称"公 司章程"），并结合《嘉事堂药业股份有限公司第七届董事会第十六次临时会议 决议的公告》及《嘉事堂药业股份有 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-26 嘉事堂药业股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 特别提示： 一、会议召开和出席情况 （一）嘉事堂2025年第二次临时股东大会于2025年7月16日下午3点在公司二 楼会议室召开。会议由公司董事长徐曦先生主持，本次股东大会按照会议议程， 采用现场表决与网络投票相结合的表决方式，审议了相关议案并作出决议。本次 股东大会的召开符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东出席的总体情况： 通过现场和网络投票的股东178人，代表股份120,441,068股，占公司有表决 权股份总数的41.2884％。 （1）通过现场投票的股东7人，代表股份117,649,375股，占公司有表决权 股份总数的40.3313％。 （2）通过网络投票的股东171人，代表股份2,791,693股，占公司有表决权 股份总数的0.9 ...

Group 1 - The company held its 16th temporary board meeting on June 30, 2025, with all 9 directors present and voting [1][2] - The board unanimously approved the proposal to amend the company's articles of association and related rules, which will be submitted for shareholder approval [1][2] - The company plans to revise the Independent Director Working System to align with legal requirements and business needs [2][3] Group 2 - The company has scheduled its second temporary shareholder meeting for July 16, 2025, in compliance with legal and regulatory requirements [3] - The decision to hold the shareholder meeting was also unanimously approved by the board [3]

Core Viewpoint - The company, Jiasitang Pharmaceutical Co., Ltd., has revised its Articles of Association to enhance corporate governance and compliance with regulatory requirements [1][2]. Summary by Relevant Sections Corporate Governance - The revision includes the addition of a section on independent directors to clarify their responsibilities and duties [1][2]. - A new chapter on the specialized committees of the board has been introduced to define their roles and responsibilities more clearly [1][2]. Terminology Adjustments - The term "shareholders' meeting" has been changed to "shareholders' assembly" throughout the document [1][2]. Compliance and Regulatory Updates - The revisions align with the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules [1][2]. - Outdated regulatory references have been removed from the Articles [1][2]. Operational Changes - The position of Chief Executive Officer has been removed, and the powers of the President have been refined [1][2]. - New provisions have been added regarding the reporting obligations if a shareholders' assembly cannot be held on time [2]. Future Actions - The proposed amendments will be submitted for approval at the second extraordinary general meeting of shareholders in 2025, after which the company will proceed with the necessary business registration procedures [2].

Core Viewpoint - 嘉事堂药业股份有限公司 is modifying its Independent Director Work System to align with updated legal regulations and business development needs, with the changes requiring approval at the upcoming shareholder meeting [1]. Summary by Sections Modifications to the Independent Director Work System - The company has proposed amendments to 11 articles of the Independent Director Work System [1]. - The specific details of the revisions are not listed in the announcement [1]. - The changes are in accordance with the Company Law (2023 Revision), the Guidelines for Listed Companies (2025 Revision), and the Shenzhen Stock Exchange Listing Rules [1]. Shareholder Involvement - Shareholders holding more than 1% of the company's issued shares can propose candidates for independent directors, subject to election by the shareholders' meeting [1]. - Nominators are prohibited from proposing candidates with whom they have a conflict of interest or other relationships that may affect the independent performance of duties [1]. - Investor protection agencies can publicly request shareholders to delegate their rights to nominate independent directors [1].

Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [4][6] - The registered capital of the company is RMB 291.707120 million [4] - The company was approved by the State-owned Assets Supervision and Administration Commission and registered in Beijing [4][6] - The company aims to utilize a sound operating mechanism to promote sustainable development and provide good returns to shareholders [6][7] Chapter Summaries Chapter 1: General Provisions - The company is established to protect the legal rights of shareholders, employees, and creditors [4] - The company was listed on the Shenzhen Stock Exchange on August 18, 2010, with an initial public offering of 40 million shares [4] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [5][6] Chapter 2: Business Objectives and Scope - The company's business objective is to promote the modernization and internationalization of the pharmaceutical industry in China [6] - The business scope includes the sale of various pharmaceutical products, medical devices, and food products [7] Chapter 3: Shares - The company issues shares in the form of stocks, with a par value of RMB 1.00 per share [8][9] - The total number of issued shares is 291.707120 million [8] Chapter 4: Party Committee - The company has established a Party Committee to ensure the implementation of national policies and oversee major decisions [14][15] Chapter 5: Shareholders and Shareholders' Meeting - The company maintains a shareholder register based on the records provided by the securities registration and settlement institution [16] - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][17] - The company must hold an annual shareholders' meeting within six months after the end of the fiscal year [25][50] Chapter 6: Shareholders' Meeting Procedures - The company must notify shareholders of meetings at least 20 days in advance for annual meetings and 15 days for temporary meetings [62][63] - The meeting must be presided over by the chairman or a designated representative [74] Chapter 7: Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [82][84] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the voting rights [82][84]

Summary of Key Points Core Viewpoint The document outlines the rules and regulations governing the shareholders' meetings of Jiasitang Pharmaceutical Co., Ltd., ensuring the protection of shareholders' rights and the proper functioning of the company in accordance with relevant laws and regulations. Group 1: General Provisions - The rules are established to regulate the behavior of the company and protect the legal rights of shareholders, ensuring efficient and lawful operation of the shareholders' meeting [1][2] - The rules apply to all shareholders, their representatives, and company officials, binding them to adhere to the established guidelines [2][3] - The shareholders' meeting is the power institution of the company, responsible for electing directors, approving financial reports, and making decisions on capital changes and major asset transactions [2][4] Group 2: Shareholders' Meeting Procedures - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [5] - Temporary meetings can be called within two months of certain events, such as insufficient directors or significant losses [6][7] - The company must report to regulatory bodies if it fails to convene a meeting within the specified time [7][8] Group 3: Proposals and Notifications - Shareholders can propose agenda items, which must comply with legal and regulatory requirements [17][18] - The board must notify shareholders of the meeting details at least 20 days in advance for annual meetings and 15 days for temporary meetings [22][23] - Proposals not included in the meeting notice cannot be voted on [10][11] Group 4: Voting and Resolutions - Voting is conducted by registered shareholders, with each share representing one vote [37] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds approval [39][40] - The company must disclose the results of the voting and the details of the resolutions passed [51][52] Group 5: Execution and Information Disclosure - The board is responsible for executing the resolutions made during the shareholders' meeting [52] - Information regarding the meetings and resolutions must be disclosed in accordance with the company's disclosure policies and relevant laws [21][22] - The rules can be amended based on changes in laws or decisions made by the shareholders' meeting [56][57]

嘉事堂药业股份有限公司 董事会议事规则 2025 年 6 月 30 日 （尚需公司 2025 年第二次临时股东大会审议） 嘉事堂药业股份有限公司 目 录 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 董事会与董事长的职权 | 1 | | 第三章 | 董事会会议制度 | 3 | | 第四章 | 董事会议事程序 | 4 | | 第五章 | 董事会会议的信息披露 | 7 | | 第六章 | 董事会决议案的执行和反馈 | 7 | | 第七章 | 附则 | 8 | 嘉事堂药业股份有限公司 第一章 总则 嘉事堂药业股份有限公司 第一条 为了确保嘉事堂药业股份有限公司（以下简称"公司"）董 事会落实股东会决议，确保董事会做出科学、迅速和谨慎的决策，规范董 事会的议事程序，根据《中华人民共和国公司法》等有关法律、行政法规、 部门规章和《嘉事堂药业股份有限公司章程》（以下简称"《公司章程》"）， 特制定本规则。 第二章 董事会与董事长的职权 第二条 根据《公司章程》的有关规定，董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营 ...